Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.48 |
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 5/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005149 | 0.90 | DRD2 (0.47) | DRD2DRD1DRD4DRD3HTR1A | |
| SCHEMBL7933893 | 0.87 | DRD2 (0.44) | DRD2DRD1DRD4DRD3HTR1A | |
| SCHEMBL7933904 | 0.86 | DRD2 (0.43) | DRD2DRD1DRD4DRD3HTR1A | |
| SCHEMBL30580523 | 0.82 | DRD2 (0.63) | DRD2DRD1DRD4DRD3HTR1A | |
| SCHEMBL22703548 | 0.81 | DRD2 (0.72) | DRD2DRD1DRD4DRD3HTR1A | |
| SCHEMBL7951055 | 0.80 | DRD2 (0.54) | DRD2DRD1DRD4DRD3HTR1A | |
| SCHEMBL7533056 | 0.78 | DRD2 (0.44) | DRD2DRD1DRD4DRD3 | |
| SCHEMBL7533054 | 0.78 | DRD2 (0.44) | DRD2DRD1DRD4DRD3 | |
| SCHEMBL21255632 | 0.77 | DRD2 (0.66) | DRD2DRD1DRD4DRD3ADRA1D | |
| SCHEMBL7785770 | 0.77 | DRD2 (0.46) | DRD2DRD1DRD4DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6232348-B1 | AGONISTS OF THE DOPAMINERGIC RECEPTORS MORE POTENT THAN DOPAMINE AND OTHER KNOWN COMPOUNDS, DEPRIVED OF INTERACTION WITH OTHER RECEPTORS AND ORALLY BIOAVAILABLE WITH A LONG TERM OF ACTION | ZAMBON GROUP S.P.A. (IT) | 2001-05-15 | — | — | US | disclosed |